Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma With Small Bowel Metastasis

BRAF mutations are estimated to be present in 2-4% of non-small cell lung carcinoma (NSCLC) cases. BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) are currently approved to treat NSCLC harboring the BRAF V600E mutation. However, the use of this new combined targeted therapy can be associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gullapalli, Keerthi, Mosalem, Osama, Varghese, Merryl T, Watat, Kevin, Hrinczenko, Borys
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396418/
https://www.ncbi.nlm.nih.gov/pubmed/34466299
http://dx.doi.org/10.7759/cureus.16431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396418/
https://www.ncbi.nlm.nih.gov/pubmed/34466299
http://dx.doi.org/10.7759/cureus.16431

Ejemplares similares